case_images: PMC9065412_01
case_images: Resolution of urticarial rash after BTK inhibitor ibrutinib therapy [(A) pre-treatment; (B) post-treatment].
case_images: fimmu-13-894464-g001.jpg
case_images: PMC9065412_01_fimmu-13-894464-g001.jpg
case_images: f1
case_images: On admission, she had intermittent fevers up to 39 C, and urticarial rashes without angioedema involving both trunk and extremities (Figure 1A). The urticarial rashes resolved completely (Figure 1B), and fatigue improved after 2 months of treatment.
case_images: Trends of laboratory findings pre- and post-BTK inhibitor ibrutinib therapy.
case_images: fimmu-13-894464-g002.jpg
case_images: PMC9065412_01_fimmu-13-894464-g002.jpg
case_images: f2
case_images: Schnitzler syndrome clinical activity score (a semiquantitative scale for rashes, pain, fever, and weight loss: 0, absent-rare; 1, moderate; 2, frequent-severe) decreased from 4 to 0, and there was moderate improvement of her anemia (hemoglobin, 10.7 g/dl) and declines in the levels of monoclonal IgMkappa (2.95 g/L) and serum IgM (7.33 g/L) (Figure 2). She tolerated the treatment well without infectious or cardiac complications, and her dose of prednisone was tapered to 15 mg daily.